Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis.

Front Public Health · 2024 · PMC11317436 · PMID 39135924

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Additionally, a descriptive analysis of OS indicated a favorable trend in both the PD-L1-positive and intention-to-treat (ITT) populations.

also in 845 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.